Results

Total Results: 1,651 records

Showing results for "described".

441. Venous-Ulcers-Treatment-Future Research (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/venous-ulcers-treatment-future_research.pdf
     January 01, 2014 - The stakeholders were asked to rank these from 1 (highest) to 3 (lowest), based on the criteria described … After determining a preliminary top-tier cutpoint according to the score sums as described above, we … After determining a preliminary top-tier cutpoint according to the score sums as described above, we … Such characteristics should be described for intervention and comparison groups to determine and adjust … All such events should be described in the articles that report the results of such studies.

442. Options for Developing a Web-Based Forum on Patient Registries (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/registries-forums_research_0.pdf
     May 01, 2014 - Stakeholders shared their perspectives on the need for a Web-based forum on patient registries and described … These and other features of the forum are described in more detail below, and the recommendations are … The technical features described below are known as Web 2.0 concepts; that is, “Web applications that … includes a Federal agency, consider the regulations to which the Web-based CoP will be subject, as described … The vendor should be template- and/or module- driven, as described above, and should offer the flexibility

443. EHC Research Protocol: Documentation Burden (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/documentation-burden-protocol.pdf
     July 26, 2023 - definitions and metrics for documentation burden are lacking.10, 11 Documentation burden has been described … physician work experiences, and documentation burden for other healthcare professionals has not been described

444. Disposition of Comments: Technical Brief 34, Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/technical-brief-34-health-worker-certification-comments.pdf
     March 27, 2020 - Once we have clearly described these goals at the outset of the report, the reader is better positioned … We would not characterize the grey literature documents as strongly in favor of certification; as described

445. McCullough (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/mccullough.pdf
     January 01, 2011 - McCullough Slide  1: An Ethical Framework for Supporting  Shared Decision Making  When Clinical Evidence is Low Laurence B. McCullough, Ph.D. Dalton Tomlin Chair in Medical Ethics and Health Policy Associate Director for Education Center for Medical Ethics and …

446. Disposition of Comments Report for Screening, Behavioral Counseling, and Referral in Primary Care To Reduce Alcohol Misuse (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/alcohol-misuse_disposition-comments.pdf
     July 10, 2012 - Regarding the NIAAA recommendations, we revised our wording of the recommendations as described in … It may be useful to add some material along the lines described below, taking care not to obscure the … The type of training received was often described fairly briefly, possibly due to space limitations … Peer Reviewer #1 Results I am not sure that the tools should be described as commonly used. … We have re-written KQ2 as described in previous responses.

447. Disposition of Comment Report for Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/wireless-motility-capsule_disposition-comments.pdf
     May 20, 2013 - As described in my comments under b) above, this has significant problems. … These distinctions are described in the methods. … These distinctions are described in the methods. … These distinctions are described in the methods. … Yes, thank you, we described this in our limitations and in our results.

448. Disposition of Comments for Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis -- Update of a 2007 Report (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoporosis-bone-fracture_disposition-comments.pdf
     March 01, 2012 - When alendronate was approved the method described in product labeling for identifying patients with … In the Executive Summary on page ES-6 and within Scope and Key Questions on page 6, denosumab is described … Chapell, Richard Executive Summary and Introduction -KQ 1 Zolendronate is described as "oral … Peer Reviewer 1 Methods: Chapter 2 Excellent and well described No response needed. … One study is described as "written by the makers of riesedronate", while another is simply described

449. Methods-Balancing-Harms-Benefits Research-2012 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-balancing-harms-benefits_research-2012.pdf
     January 01, 2012 - The team also evaluated articles citing any of the above articles to determine whether they described … We described all quantitative approaches using the final list of key characteristics and unified the … As described earlier in this report, the Gail/NCI approach calculates a benefit and harm comparison … The decisions are parallel to those described in this report under ―evidence generation.‖ In the EPC … In Objective 2, we described the methodological characteristics of existing quantitative approaches

450. Effectiveness of Treatments for Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetic-neuropathy_research-protocol.pdf
     May 09, 2016 - DPN is usually described as glove-stocking distribution of numbness, sensory loss, paresthesia (abnormal … ulcerations.14 Although DPN is not an outcome in studies addressing these comorbid conditions, they may be described … the Review Inclusion and exclusion criteria are provided in Table A, based on the PICOTS framework described … As described in Section A. we will assess systematic reviews with ROBIS and, where possible, will use

451. S149 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s149.pdf
     October 01, 2007 - Using the algorithm described in the methods, we estimated propensity scores for each treatment regimen … As described in the algorithm, the expected outcome (charges) for each strata was estimated by linear … As described in step 3), the transitional probabilities in columns 5 and 6 were estimated by proportional … As described in step 4), the expected outcome (in this case, charges) for each strata was estimated by

452. Assessing the Impact of Indexing Performance Measure Codes on the Perceived Value of EPC Reports to Health Systems (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-assessing-impact.pdf
     September 01, 2018 - Health-System Representative 2 12 min 3 min 11 min 5 min Note: While the participants are described … As described above, these responses informed improvements in the quality measure index before we began … In the phase two assessment, we used the two exercise scenarios and three query questions described … Health-System Representative 2 12 min 3 min 11 min 5 min Note: While the participants are described

453. Treatment for Restless Legs Syndrome Disposition of Comments Report (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/restless-legs_disposition-comments.pdf
     November 27, 2012 - We have further described “mimic” conditions. … We included studies if they reported our described outcomes of interest even if IRLS scores were not … Primary outcomes were determined by us, discussed with our TEP and described in our protocol. … & Affiliation Section Comment Response Peer Reviewer #6 Results The detail of the results as described

454. Pneumonia-Antibiotic-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pneumonia-antibiotic-treatment_executive.pdf
     November 01, 2014 - 2005 by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) described … independently reviewed each full-text article for inclusion or exclusion based on the eligibility criteria described … Further, methods were not clearly described. … principles and clinical trial efficacy data.1 Nevertheless, the effectiveness of the dosing strategies described

455. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-atrial-fibrillation_research-protocol.pdf
     January 30, 2012 - Inclusion/Exclusion of Studies in the Review We will apply the inclusion and exclusion criteria described … Data needed to assess quality and applicability, as described in the Methods Guide,25 will also be abstracted … The strength of evidence will be assessed by using the approach described in AHRQ’s Methods Guide.25,28 … Assessing Applicability We will assess applicability across our key questions using the method described

456. Medical Therapies for Children With Autism Spectrum Disorder—An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-medical-executive-170505.pdf
     May 01, 2017 - Dietary and nutritional studies included some younger children, with severity of autism not well described … Studies also typically described interventions fully, used standardized diagnostic processes and blinded … Harms reporting varied across studies; some studies amply described how harms were tracked, while others … Harms reporting varied across studies; some studies amply described how harms were tracked, while others

457. Prostate-Cancer-Test Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_executive.pdf
     April 01, 2013 - The Key Questions (KQs) relate to the three proposed scenarios described above: KQ1: In patients with … KQ 1 and 2: Initial and Repeat Biopsies In addition to the 9 studies described above, another 15 studies … provided sufficient data to compare the diagnostic accuracy of PCA3 with tPSA elevations, using the five described … Performance of PCA3 and comparators in a broader range of health care settings may differ from that described

458. Undescended-Testicle Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/undescended-testicle_executive.pdf
     December 01, 2012 - If a study had negative imaging for all subjects, if the imaging techniques were not adequately described … We used the approach to strength of evidence assessment described in the Effective Health Care Program … Only four studies adequately described selection criteria for the participants, and three studies provided … surgical approach was assessed independently for ability to achieve testicular descent because, as described

459. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
     January 01, 2015 - Peer Reviewer #3 Results Are the characteristics of the studies clearly described? Yes. … In the ‘Summary’ column of these tables effects are described as small, medium/moderate, and large but … We described these studies in the text. … We made a note of this in Table 2, where the drugs are first described. … DPP4 inhibitors are misleadingly described as less effective.

460. Comparative Effectiveness Review No. 241_Physical Activity and the Health of Wheelchair Users: A Systematic Review in Multiple Sclerosis, Cerebral Palsy, and Spinal Cord Injury (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-241-physical-activity-wheelchair-evidence-summary-updated.pdf
     October 01, 2021 - Guidance (https://effectivehealthcare.ahrq.gov/topics/cer-methods-guide/overview), and these are described